Home

Robert L. Rosiello

CIK 1645041 · EVP, Corp Dev & Strategy · last filed 2026-07-10

Robert L. Rosiello is an EVP, Corp Dev & Strategy who has filed 18 SEC Form 4 insider transactions across 5 companies since 2022. The most recent filing, for MCRB, was dated Jul 10, 2026. 10 SEC filings were submitted jointly with Bausch Health Companies Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

5

Total Filings

18

Lifetime Open-Market Net

$0

Filer Profile

Reported Address
188 EAST BLAINE STREET
SUITE 400
SEATTLE, WA 98102
Related Filers
Bausch Health Companies Inc. — 10 joint filings, latest 2016-12-07
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
MCRB Director — $5.01 — $0 3 2026-07-10
SANA Director — $3.13 — $0 2 2026-06-05
Omega Therapeutics, Inc. (OMGA) Delisted Director — $0.14 — $0 1 2024-10-04
Evelo Biosciences, Inc. (EVLO) Delisted Director — $0.00 — $0 2 2023-06-12
Axcella Health Inc. (AXLA) Delisted Director — $0.40 — $0 1 2022-11-18

Recent Filings

18 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-10 MCRB Grant (A) — $0 EDGAR
2026-07-02 MCRB Grant (A) — $0 EDGAR
2026-06-05 SANA Grant (A) — $0 EDGAR
2025-08-06 MCRB Grant (A) — $0 EDGAR
2025-06-09 SANA Grant (A) — $0 EDGAR
2024-10-04 Omega Therapeutics, Inc. (OMGA) Delisted Grant (A) — $0 EDGAR
2023-06-12 Evelo Biosciences, Inc. (EVLO) Delisted Grant (A) — $0 EDGAR
2023-04-18 Evelo Biosciences, Inc. (EVLO) Delisted Grant (A) — $0 EDGAR
2022-11-18 Axcella Health Inc. (AXLA) Delisted Grant (A) — $0 EDGAR
2016-12-07 — Tax (F) −14,687 -$264.4K
Showing 1–10 of 18
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.